' Ravgen''' Inc., is a privately owned biotech company founded by Chairman and C.E.O. Dr. Ravinder Dhallan. Ravgen Inc. is known for its research in the prenatal diagnostic field and its development of non-invasive prenatal diagnosis testing which was published in The Lancet, the Journal of the American Medical Association., and the New England Journal of Medicine. These publications received worldwide press in The Times, The Washington Post, CNN Fortune Small Business, and The New York Times Ravgen was founded in 2000 in Columbia, Maryland by Dr. Ravinder Dhallan. Dr. Dhallan received doctorates in medicine and biomedical engineering at The Johns Hopkins University as well as an MBA from the Wharton School of Business at the University of Pennsylvania. The CEO and founder of the company held residency positions in oncology at Massachusetts General Hospital and in emergency medicine at York Hospital in York, PA before becoming an attending physician in the Department of Emergency Medicine at Holy Cross Hospital in Silver Spring, MD. Dr. Dhallan left his position at Holy Cross in 2000 in order to start his own company, Ravgen, with the pursuit of developing a safer prenatal diagnostic exam. At the time the only options available to patients were invasive with a chance of miscarriage or lacked in accuracy. Since its start in 2000, Ravgen has developed and patented a variety of safe, accurate prenatal diagnostic tests that simply require a blood draw from the mother. The company's core technology is based on its ability to increase the percentage of fetal DNA that is found in the maternal bloodstream, something that scientists have attempted to do for decades with little success. With this breakthrough in medicine, Ravgen is able to offer safe, noninvasive, pre-birth testing alternatives for expectant mothers and give them the knowledge they need to prepare for their pregnancies.
Ravgen has published its genetic research in internationally recognized, peer reviewed articles including JAMA in 2004, The Lancet in 2007, and the New England Journal of Medicine in 2012. In addition, Ravgen has received local and global media coverage on its non-invasive prenatal DNA testing. Articles about the company and its research have been published in CNN Fortune Small Business, The Times, The Washington Post, Technology Review MIT, BBC News, Reuters, Health Day, WUSA, and The New York Times.
